IL6 and scleroderma: Tocilizumab and sarilumab are fully humanized monoclonal antibodies that block IL-6 binding to soluble IL-6 receptor, thereby inhibiting IL-6 signaling, a crucial pathway in the pathogenesis of scleroderma, which regulates fibroblast activity, stimulates collagen production, and inhibits the synthesis of collagenases.